Dynavax Technologies
DVAX
#5495
Rank
A$1.92 B
Marketcap
A$16.42
Share price
-0.41%
Change (1 day)
-18.05%
Change (1 year)

Revenue for Dynavax Technologies (DVAX)

Revenue in 2025 (TTM): A$0.51 Billion

According to Dynavax Technologies 's latest financial reports the company's current revenue (TTM ) is A$0.49 Billion. In 2024 the company made a revenue of A$0.44 Billion an increase over the revenue in the year 2023 that were of A$0.34 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Dynavax Technologies from 2004 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$0.51 B15.23%
2024 A$0.44 B30.74%
2023 A$0.34 B-67.9%
2022 A$1.06 B75.2%
2021 A$0.60 B901.23%
2020 A$60.54 M20.35%
2019 A$50.3 M332.26%
2018 A$11.63 M2678.31%
2017 A$0.41 M-97.27%
2016 A$15.31 M231.47%
2015 A$4.62 M-54.67%
2014 A$10.19 M-19.17%
2013 A$12.61 M34.94%
2012 A$9.34 M-55.66%
2011 A$21.07 M-10.6%
2010 A$23.57 M-47.47%
2009 A$44.88 M-14.64%
2008 A$52.57 M226.17%
2007 A$16.11 M162.16%
2006 A$6.14 M-69.3%
2005 A$20.02 M4.64%
2004 A$19.14 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Agenus
AGEN
A$0.16 B-67.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
A$15.14 B 2,945.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
A$96.64 B 19,334.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
A$43.75 B 8,700.23%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$87.45 B 17,486.85%๐Ÿ‡ฌ๐Ÿ‡ง UK
GlaxoSmithKline
GSK
A$63.71 B 12,714.22%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
A$94.46 B 18,896.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$25.23 B 4,975.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Amgen
AMGN
A$54.11 B 10,783.35%๐Ÿ‡บ๐Ÿ‡ธ USA